Skip to main content
. 2016 Jun 17;7(45):72746–72757. doi: 10.18632/oncotarget.10125

Figure 4. Effect of CTGF siRNA, CCND1 siRNA and miR-26b on the expression of CTGF and CCND1 in rPASMCs.

Figure 4

A. Effect of introduction of anti-CTGF siRNA, anti-CCND1 siRNA, has-miR-26b mimics and control on the mRNA expression level of CTGF in hPASMCs (p<0.01); B. lower panel: Effect of introduction of anti-CTGF siRNA, anti-CCND1 siRNA, has-miR-26b mimics and control on the protein expression level of CTGF in hPASMCs, as determined by western blot; upper panel: densitometric analysis of the western blot results underneath (p<0.01); C. Effect of introduction of anti-CTGF siRNA, anti-CCND1 siRNA, has-miR-26b mimics and control on the mRNA expression level of CCND1 in hPASMCs (p<0.01); D. lower panel: Effect of introduction of anti-CTGF siRNA, anti-CCND1 siRNA, has-miR-26b mimics and control on the protein expression level of CCND1 in hPASMCs, as determined by western blot; upper panel: densitometric analysis of the western blot results underneath (p<0.01). All experiments were repeated three times (N value=3).